Physician profile
Daniel G Smith
NPI 1649439464
$2,793.75
in general payments reported to CMS, 2019-2025
28 companies · $14.73 in 2025
The $14.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $782 · 2021: $1,435 · 2022: $218 · 2023: $45.86 · 2024: $33.84 · 2025: $14.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.39 | 2020-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $207.44 | 2020-2021 | |
| Pfizer INC. | $206.47 | 2020-2024 | |
| Glaxosmithkline, LLC. | $197.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.75 | 2019-2021 | |
| Abbvie INC. | $193.64 | 2021-2023 | Qulipta |
| Amgen INC. | $188.51 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $186.62 | 2019-2022 | |
| Boston Scientific Corporation | $122.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.52 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $114.30 | 2020-2021 | |
| Lilly USA, LLC | $96.98 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.47 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $84.42 | 2020-2021 | |
| Eisai INC. | $73.79 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69.07 | 2020-2022 | |
| Allergan, INC. | $52.44 | 2020 | |
| Esperion Therapeutics, INC. | $41.47 | 2021 | |
| Scilex Pharmaceuticals INC. | $35.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.67 | 2021-2024 | |
| Dexcom, INC. | $29.19 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $25.65 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.40 | 2021 | |
| Abbott Laboratories | $21.91 | 2021 | |
| Sanofi Pasteur INC. | $14.54 | 2019 | |
| Ibsa Pharma INC. | $13.49 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.30 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.